Esophageal squamous cell carcinoma (ESCC) is a severe health threat, being a predominant subtype of esophageal cancer and ...

Fighting cancer can seem like a deadly game of chance. While some patients may respond well to certain treatments, others might not be as fortunate. Doctors and scientists have long struggled to ...

A new study by investigators from Mass General Brigham uncovers how a novel immunotherapy prevents squamous cell carcinoma, ...

The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...

When it comes to performance, Phio Pharmaceuticals has been outshining broader market indices. The company’s stock has rocketed up by an impressive 318.95% year-to-date (YTD), vastly outperforming the ...

Two independent studies reveal that disease progression is delayed by combining two targeted therapies with the traditional ...

"FDA grants ODD to Tempest’s hepatocellular carcinoma treatment" was originally created and published by Pharmaceutical ...

A new study uncovers how a novel immunotherapy prevents squamous cell carcinoma, with benefits lasting five years after treatment. This therapy is the first to activate specific components of the ...

Following a recent trial, doctors at The Christie Hospital are optimistic about the study of HMBD-001 in the treatment of ...

Scientists have made a discovery which could lead to the first change in standard liver cancer treatment in 20 years. Two ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...